oa SA Pharmaceutical Journal - An update on sildenafil in the treatment of pulmonary arterial hypertension in the neonate : review
|Article Title||An update on sildenafil in the treatment of pulmonary arterial hypertension in the neonate : review|
|© Publisher:||Medpharm Publications|
|Journal||SA Pharmaceutical Journal|
|Affiliations||1 Sefako Makgatho Health Sciences University and 2 Sefako Makgatho Health Sciences University|
|Publication Date||Jan 2015|
|Pages||22 - 25|
|Keyword(s)||Neonate, Pulmonary arterial hypertension (PAH), and Sildenafil|
Pulmonary arterial hypertension (PAH) refers to a group of diseases that are characterised by high pressure in the pulmonary artery and by pulmonary vascular resistance. Persistent PAH in the newborn is a condition whereby the pulmonary artery pressure does not decrease after birth, and may occur in as many as 6.8 in 1 000 live births. Phosphodiesterase type 5 (PDE-5) is the predominant PDE isoform in the lung which metabolises cyclic guanosine monophosphate (cGMP), and is upregulated in conditions associated with PAH. Thus, by selectively inhibiting PDE-5, the accumulation of intracellular cGMP is promoted by sildenafil citrate and nitric oxide-mediated vasodilatation is also enhanced. The article provides information on associated dosing regimens and reconstitution guidelines.
Article metrics loading...